Filing Flows › Humacyte (HUMA) › Q1 2026 › vs Q4 2025
Humacyte (HUMA) Q1 2026 vs Q4 2025 (quarter over quarter)
Humacyte's revenue rose $28K (+6%) from $467K in Q4 2025 to $495K in Q1 2026.
Humacyte, Q1 2026: revenue $495K (-4% year over year), net loss $17.6M, operating cash flow −$25.1M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $495K | $467K | $28K | +6% |
| Other income, net | $11.3M | $6.0M | $5.3M | +88% |
| Net loss | $17.6M | $24.8M | −$7.2M | -29% |
| Costs & expenses | $29.4M | $31.3M | −$1.9M | -6% |
| Operating costs | $29.4M | $31.3M | −$1.9M | -6% |
| Cost of revenue | $2.0M | $9.1M | −$7.0M | -78% |
| Research & development | $19.5M | $14.6M | $4.9M | +33% |
| Operating cash sources | $29.6M | $29.9M | −$319K | -1% |
| Depreciation | $1.3M | $1.3M | $1K | +0.1% |
| Share-based compensation | $3.2M | $2.5M | $700K | +28% |
| Cash used in operations | $25.1M | $26.1M | −$1.0M | -4% |
| Net loss absorbed | $17.6M | $24.8M | −$7.2M | -29% |
| Working capital & other | $12.0M | $5.1M | $6.9M | +134% |
Questions
How much did Humacyte's revenue grow quarter over quarter in Q1 2026?
Humacyte's revenue rose $28K (+6%) from $467K in Q4 2025 to $495K in Q1 2026.